A Phase 2 interventional study of NIO752 and Placebo in Progressive Supranuclear Palsy, Corticobasal Degeneration and Frontotemporal Lobar Degeneration, sponsored by Novartis Pharmaceuticals. Not yet recruiting. Open to participants aged 41 Years to 81 Years. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a phase II study intended to evaluate the safety, tolerability and pharmacodynamics of NIO752 in participants with primary tauopathies. Eligible participants will be randomized to receive either NIO752 or placebo during the double-blind treatment period followed by an Open-label Extension (OLE).
This is a randomized, double-blind (DB), placebo-controlled, parallel group, basket study to evaluate the safety, tolerability and pharmacodynamics of NIO752 in participants with PSP non-RS (Cohort 1), CBS non-AD (Cohort 2), and MAPT-FTLD (Cohort 3), followed by an OLE.
The study participants (16 per cohort) will be randomly allocated to either NIO752 or placebo treatment.
The study includes a screening period, a Double Blind treatment period, an Open-Label extension treatment period, and and a follow-up period until End-of-Study (EoS) visit.
171 studies on the registry are indexed under Supranuclear Palsy, Progressive; 51 are open to participants now.
This study's planned enrollment of 48 is above the median of 43 across 102 interventional studies indexed under Supranuclear Palsy, Progressive.
Browse Supranuclear Palsy, Progressive studies →Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Common across all cohorts:
Cohort specific criteria:
Inclusion criteria (PSP non-RS): Diagnosis of mild-moderate, probable PSP non-RS as per MDS-PSP 2017 criteria with symptoms onset ≤5 years prior to Screening.
Inclusion criteria (CBS non-AD): Diagnosis of possible or probable CBD as per the 2013 consensus criteria, with CBS phenotype and symptom onset ≤5 years prior to screening. Individuals meeting criteria for probable CBD with non-CBS phenotypes (e.g., behavioral variant) are excluded to maintain consistency with the CBS non-AD target population.
Inclusion criteria (MAPT-FTLD): Carriers of a known pathogenic MAPT mutation based on existing evidence of prior genetic testing.
Exclusion Criteria:
Medical conditions that would as per Investigator's judgement prevent the participant from undergoing lumbar puncture (LP), including but not limited to:
Current dermatological infection at the LP site and/or significant skin alterations at the planned LP site:
Other protocol defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NIO752 solution
Drug: NIO752
Placebo solution
Drug: Placebo
NIO752 solution
Drug: NIO752
Placebo solution
Drug: Placebo
NIO752 solution
Drug: NIO752
Placebo solution
Drug: Placebo
Antisense Oligonucleotide Solution
Placebo solution
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) in double blind period
Number of participants with TEAEs including SAEs, AESIs, and AEs leading to treatment interruption/discontinuation or dose reduction.
Time frame: From first treatment administration up to week 48
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) in open-label extension
Number of participants with TEAE, AESIs, SAEs, AEs leading to treatment interruption/discontinuation or dose reduction in OLE.
Time frame: From first treatment administration in OLE period up to week 96
Change from baseline in clinical laboratory evaluations
Number of participants with laboratory test abnormalities.
Time frame: From baseline up to week 96
Change from baseline in vital signs
Number of participants with clinically notable vital signs.
Time frame: From baseline up to week 96
Change from baseline in ECG parameters
Number of participants with clinically notable ECG abnormalities.
Time frame: From baseline up to week 96
Suicidality assessment using the C-SSRS
The number and percentage of participants reporting any suicidal ideation and behavior in Columbia Suicide Severity Rating Scale will be summarized
Time frame: From baseline up to week 96
Change from baseline in target engagement biomarker
Change from baseline in biomarker as measure of target engagement.
Time frame: Baseline, week 24, week 48 and week 84
Change from baseline in neurodegeneration biomarker
To assess NIO752 effect on neurodegeneration.
Time frame: Baseline, week 24, week 48 and week 84
Pharmacokinetic concentrations of NIO752
Observed concentration of NIO752
Time frame: Baseline, week 12, 24, 36, 48, 60, 72 and 84
NIO752 antidrug antibodies (ADA)
To assess immunogenicity of NIO752
Time frame: Baseline, week 12, 24, 36, 48, 60, 72 and 84
No study locations are listed for this record.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Data sharing details ↗ · www.clinicalstudydatarequest.com
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Mar 2029, 29 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: NIO752
Supranuclear Palsy, Progressive →